It is made available under a CC-BY 4.0 International license .

- 1 Developing deep learning-based strategies to predict the risk of hepatocellular carcinoma
- 2 among patients with nonalcoholic fatty liver disease from electronic health records
- 3
- 4 Zhao Li, Ph.D.¹, Lan Lan, Ph.D.¹, Yujia Zhou, M.S.¹, Ruoxing Li, M.S.¹, Kenneth D. Chavin,
- 5 M.D., MBA, PhD², Hua Xu, Ph.D.³, Liang Li, Ph.D.⁴, David J. H. Shih, Ph.D.⁵, W. Jim Zheng,
- 6 Ph.D.^{1,*}
- 7 ¹McWilliams School of Biomedical Informatics, University of Texas Health Science Center at Houston, 7000
- 8 Fannin Street, Suite 600, Houston, Texas, 77030
- ⁹ ² Department of Surgery, Case Western Reserve University School of Medicine, 11100 Euclid Ave, Cleveland OH
 44106
- 11 ³ Yale School of Medicine
- ⁴ Department of Biostatistics, University of Texas MD Anderson Cancer Center, 1400 Pressler Street, FCT4.6008,
- **13** Houston TX 77030
- ⁵ School of Biomedical Sciences, University of Hong Kong
- 15 *Corresponding Author: W. Jim Zheng, PhD, McWilliams School of Biomedical Informatics, University of Texas
- 16 Health Science Center at Houston, 7000 Fannin St, Houston, TX 77030, USA (wenjin.j.zheng@uth.tmc.edu)

It is made available under a CC-BY 4.0 International license .

18 Abstract

Background: Deep learning models showed great success and potential when applied to many 19 biomedical problems. However, the accuracy of deep learning models for many disease 20 21 prediction problems is affected by time-varying covariates, rare incidence, and covariate 22 imbalance when using structured electronic health records data. The situation is further 23 exasperated when predicting the risk of one disease on condition of another disease, such as the hepatocellular carcinoma risk among patients with nonalcoholic fatty liver disease due to slow, 24 chronic progression, the scarce of data with both disease conditions and the sex bias of the 25 26 diseases. **Objective:** The goal of this study is to investigate the extent to which time-varying covariates, 27 28 rare incidence, and covariate imbalance influence deep learning performance, and then devised 29 strategies to tackle these challenges. These strategies were applied to improve hepatocellular carcinoma risk prediction among patients with nonalcoholic fatty liver disease. 30 **Methods**: We evaluated two representative deep learning models in the task of predicting the 31 32 occurrence of hepatocellular carcinoma in a cohort of patients with nonalcoholic fatty liver disease (n = 220,838) from a national EHR database. The disease prediction task was carefully 33 34 formulated as a classification problem while taking censorship and the length of follow-up into consideration. 35 36 **Results:** We developed a novel backward masking scheme to evaluate how the length of 37 longitudinal information after the index date affects disease prediction. We observed that modeling time-varying covariates improved the performance of the algorithms and transfer 38

39 learning mitigated reduced performance caused by the lack of data. In addition, covariate

40 imbalance, such as sex bias in data impaired performance. Deep learning models trained on one

It is made available under a CC-BY 4.0 International license .

- 41 sex and evaluated in the other sex showed reduced performance, indicating the importance of
- 42 assessing covariate imbalance while preparing data for model training.
- 43 Conclusions: Devising proper strategies to address challenges from time-varying covariates,
- 44 lack of data, and covariate imbalance can be key to counteracting data bias and accurately
- 45 predicting disease occurrence using deep learning models. The novel strategies developed in this
- 46 work can significantly improve the performance of hepatocellular carcinoma risk prediction
- 47 among patients with nonalcoholic fatty liver disease. Furthermore, our novel strategies can be
- 48 generalized to apply to other disease risk predictions using structured electronic health records,
- 49 especially for disease risks on condition of another disease.
- 50

51 Keywords: deep learning, electronic health records, sex bias, hepatocellular carcinoma,

52 nonalcoholic fatty liver disease

It is made available under a CC-BY 4.0 International license .

54 Introduction

Hepatocellular carcinoma (HCC) is one of the most common types of primary liver cancer in 55 adults and one of the leading causes of cancer-related deaths worldwide [1, 2]. Besides the well-56 57 known risk factors associated with HCC, e.g., hepatitis C, hepatitis B and alcoholic cirrhosis, 58 nonalcoholic fatty liver disease (NAFLD) has also been linked to HCC in the United States and 59 worldwide [3]. The previous analysis identified non-alcoholic steatohepatitis accounting for the underlying etiology in a small-scale analysis [4] and recognized sex as an important factor. 60 However, these previous studies were relatively small with very limited number of patients who 61 62 developed HCC after diagnosis of the liver diseases. The extensive deployment of electronic health records (EHR) systems in the United States has 63 64 accumulated vast amounts of patient medical history data [5]. Meanwhile, artificial intelligence, especially deep learning has shown great promise in clinical informatics research at large scale. 65 Various deep learning approaches have been employed to predict HCC risk using clinical data. 66 Ioannou et al. [6] applied Recurrent Neural Network to predict the HCC development among 67 patients with hepatitis C virus-related cirrhosis in the national Veterans Health Administration 68 database. Similarly, researchers also employed Convolutional Neural Network-based models to 69 70 predict HCC development among viral hepatitis patients and patients with cirrhosis [7, 8]. These studies showed deep learning methods can achieve superior performance over the conventional 71 72 regression models but none of them applied deep learning for predicting HCC development in 73 patients with NAFLD [9-11]. Therefore, applying the latest deep learning approaches to analyze EHR data from large cohorts of patients for accurate assessment of the risk of developing HCC 74 75 in patients with NAFLD is desirable.

It is made available under a CC-BY 4.0 International license .

76 Machine learning models [12, 13], and more recently, deep learning models [14-16], are used for disease prediction on structured data from EHR. Despite their great promise and 77 improvement in performance, several inherent data challenges persist in applying deep learning-78 79 based approaches for disease risk prediction. For example, censoring occurs when certain data 80 points within a study are either incomplete or unknown due to factors such as being outside the 81 study's time frame or scope, or other limitations. Censored data is very common in clinical, especially EHR-based research, because many patients will lose follow-up during the entire time 82 frame of the clinical event of interest [17-19]. Current deep learning models often do not account 83 84 for censoring in time-to-event data or have ad hoc design [19]. However, not properly accounting for censorship would lead to biased estimates of disease risk [20]. To utilize well-established 85 86 machine learning algorithms for classification while handling censorship in time-to-event data, 87 Craig et al. [21, 22] proposed to stack the features and outcomes of survival data at each timepoint into a single large table where the event time is cast as an additional covariate. 88 However, this approach would lead to significant computing challenge for large datasets that are 89 90 very common in EHR data. Additionally, the slow, chronic progression of diseases poses another 91 challenge for disease risk prediction, as delayed diagnosis makes it difficult to predict future 92 disease [23]. Time-varying covariates contain longitudinal information that could be important in disease risk prediction but have not been thoroughly evaluated while applying deep learning-93 94 based approaches [24-26]. Furthermore, deep learning-based approaches rely on large amounts 95 of data for good performance, but predicting the risk of a disease in the context of another preexisting disease typically results in small cohorts, as patients must satisfy the selection criteria 96 97 for both diseases. To tackle this issue of data insufficiency, clinical concepts embeddings 98 generated from a large EHR dataset were imported as initial embeddings based on other disease

99 prediction tasks [27]. A transformer-based model was pretrained by masked language modeling on a large EHR database and can be finetuned to downstream tasks with small sample sizes [28]. 100 However, the improvement of using these pretrained embeddings or models depends largely on 101 102 the relatedness of the learning task and data during the pretraining stage and could be limited if 103 the training data is dissimilar to the target data [29]. Besides these methodologic considerations, 104 accurate predictions from machine learning models also strongly depend on the quality of input features and the training set [30]. Machine learning models may generate inferior or unreliable 105 106 predictions if the unlabeled samples have dissimilar characteristics compared with the training 107 set.

108 In this study, we investigate the impact of these challenges on performance of deep learning 109 models in predicting disease risks from structured EHR data. We focus on hepatocellular 110 carcinoma (HCC), one of the most common types of primary liver cancer in adults and one of the leading causes of cancer-related deaths worldwide [1, 2]. We predicted HCC risk among a large 111 112 retrospective cohort of NAFLD patients (47% male and 53% female) from an EHR database 113 containing records for over 68 million patients in the U.S. We formulated disease prediction as a 114 classification problem while accounting for censoring and developed a novel approach to address 115 delayed diagnosis by masking data before the diagnosis of disease. Our results demonstrate that 116 time-varying covariate is a key factor influencing predictive performance. In addition, we 117 established a new transfer learning paradigm for deep learning-based disease prediction on EHR 118 data. Finally, we evaluated the impact of sex bias on deep learning performance and identified 119 sex-specific features for HCC progression. Our study offers several key contributions. Firstly, we 120 propose new approaches to preprocess event-to-event data from electronic health records 121 (EHRs), which can improve the accuracy of downstream machine learning models. Secondly, we

It is made available under a CC-BY 4.0 International license .

122	identify biases in EHR data that were previously overlooked or neglected, highlighting the
123	importance of careful data preprocessing in medical research. Finally, we propose a novel
124	strategy, backward masking, to deal with the issue of delayed diagnosis which is very common in
125	EHR data analysis. Given the abundance of existing machine learning models and the vast
126	amounts of EHR data available, we believe that addressing the challenges associated with
127	applying machine learning to EHRs has broader implications for related fields as well.
128	
129	Methods
130	Study Cohorts
131	The data in this study were extracted from the Cerner Health Facts® database, which contains
132	deidentified EHR data for more than 68 million patients for the years 2000 to 2017. We extracted
133	all encounter records for patients who satisfied the inclusion and exclusion criteria for each
134	patient set described below. These encounter records contain data about demographics,
135	diagnoses, medications, lab tests, and clinical events. Since Cerner Health Facts® used both
136	International Classification of Diseases version 9 and version 10 for patient diagnoses, we
137	standardized the medical codes by converting all version 9 codes to version 10 codes. We used

It is made available under a CC-BY 4.0 International license .

- 139 Using the Cerner Health Facts® database, we created a set of patients with NAFLD and a case-
- 140 control set. Figure 1 shows the study flowchart.



illustration. Propensity score matching was conducted for all periods of backward masking.



It is made available under a CC-BY 4.0 International license .

149	date of NAFLD. Since the data is used to evaluate both baseline and deep learning methods, any
150	bias introduced by this exclusion criteria will have minimal impact on our method evaluation and
151	is outweighed by the benefit of resulting high quality data as demonstrated by many studies [31-
152	34]. We excluded patients with hepatitis B or hepatitis C virus to eliminate the impact of these
153	well-known risk factors for HCC. Finally, we excluded patients with a history of alcoholism or
154	chronic hepatitis before the index date (Figure 1).
155	
156	Case-control patient set. To increase the size of the NAFLD cohort for training a deep learning
156 157	<i>Case-control patient set.</i> To increase the size of the NAFLD cohort for training a deep learning model to perform HCC prediction, we extracted all patients with HCC from the Cerner Health
156 157 158	<i>Case-control patient set.</i> To increase the size of the NAFLD cohort for training a deep learning model to perform HCC prediction, we extracted all patients with HCC from the Cerner Health Facts® dataset and added a set of healthy patients as matched controls who were at least 18 years
156 157 158 159	<i>Case-control patient set.</i> To increase the size of the NAFLD cohort for training a deep learning model to perform HCC prediction, we extracted all patients with HCC from the Cerner Health Facts® dataset and added a set of healthy patients as matched controls who were at least 18 years old at the first encounter and had not been diagnosed with NAFLD. A matching control patient
156 157 158 159 160	Case-control patient set. To increase the size of the NAFLD cohort for training a deep learning model to perform HCC prediction, we extracted all patients with HCC from the Cerner Health Facts® dataset and added a set of healthy patients as matched controls who were at least 18 years old at the first encounter and had not been diagnosed with NAFLD. A matching control patient was randomly sampled for each HCC patient at a ratio of 10:1 based on gender, age at the first
156 157 158 159 160 161	Case-control patient set. To increase the size of the NAFLD cohort for training a deep learning model to perform HCC prediction, we extracted all patients with HCC from the Cerner Health Facts® dataset and added a set of healthy patients as matched controls who were at least 18 years old at the first encounter and had not been diagnosed with NAFLD. A matching control patient was randomly sampled for each HCC patient at a ratio of 10:1 based on gender, age at the first encounter, and duration from the first to the last encounter (Figure 1).

- 162 The characteristics of the NAFLD cohort and the case-control set are summarized in **Table 1**.
- 163 Table 1. Summary characteristics of patient sets.

Patient set	# of patients	# of HCC patients	# of male patients	# of female patients	Avg. # of encounters per patient	Avg. # of codes in an encounter
Case-control set	57,691	8,702	28,881	28,810	24.14	8.77
NAFLD cohort	220,838	272	88,637	132,201	56.58	10.46

164

165 Study design

166 Deep learning models are usually designed for classification, and often do not account for

167 censoring. We are interested in applying state-of-the-art deep learning models designed for

168 classification to identify risk factors, rather than to estimate absolute risk precisely. However, not

It is made available under a CC-BY 4.0 International license .

169 properly accounting for censorship can lead to biased estimates of disease risk [20]. Therefore,

170 we carefully formulated disease prediction as a classification problem while considering

171 censorship and the length of follow-up [22, 35].

172 We defined the event as the occurrence of HCC within 10 years after the index date using four 173 individual patients as examples (Figure 2). Patients lost to follow-up for any reason, including 174 death, were considered right-censored. We selected and labeled patients as shown in Figure 2. 175 Patients who developed HCC after 10 years after index date were labeled as negative (Patient 1); those who did not develop HCC after the index date and were still in the Cerner Health Facts® 176 database more than 10 years after the index date were also labeled as negative (Patient 2); the 177 178 remaining patients were labeled as positive if they developed HCC within 10 years after index 179 date (Patient 3); and all other patients were excluded (Patient 4). This last group of patients 180 includes those who did not develop HCC but had less than 10 years of follow-up after the index date. Since there is insufficient information about whether these patients had developed HCC 181 182 within 10 years of the index date, they do not have clear labels about their disease status at this 183 time point, and they are thus not informative [17]. Under our criteria, patients who developed HCC before NAFLD were excluded, because we are interested in progression from NAFLD to 184 185 HCC. Moreover, patients who developed HCC within 2 years after the index date were also 186 excluded, since we focused on progression from NAFLD to HCC. If HCC is developed too 187 quickly after NAFLD diagnosis, that means the patient might have HCC at the time NAFLD was 188 diagnosed. This exclusion criterion might help the deep learning model pick up more meaningful 189 predictive features for HCC prediction. Hence, the classification task for deep learning models is 190 to estimate whether a patient with NAFLD will develop HCC within 10 years.

191 After the labeling process and backward masking (described below), we conducted propensity



192 score matching to balance the ratio of positive and negative samples using the "MatchIt" R

Figure 2. Study design. Formulation of disease prediction as a classification problem while accounting for censoring. Patients were included only if they had at least one year of medical history (dashed line at left) in the database. Samples were filtered and labeled as shown.

193 package. Features for conducting propensity score matching contain the mean and standard 194 deviation of the time intervals among two successive encounters and the number of encounters 195 for a patient. For each positive sample, we selected one control by performing greedy nearest-196 neighbor matching (Figure 1). The Figure S1 shows the distribution of negative samples is 197 closer to the positive samples after propensity score matching.

198

199 Deep learning models and features

- 200 We used the two most representative deep learning models for our study: RETAIN is a
- 201 classification-based model [24] and DeepHit is a deep survival model [25, 26]. RETAIN is a
- recurrent neural network-based model that uses an attention mechanism [24]. The gated recurrent

203 unit inside RETAIN can efficiently use longitudinal medical information to predict disease progression. Meanwhile, a two-level attention module on top of the gated recurrent unit layers 204 205 can generate the contribution weights of each feature (medical code) to the final prediction. 206 Specifically, RETAIN first represents each medical code that is recorded in an encounter with a 207 fixed-size, randomly initialized vector. All medical codes in an encounter are summed together 208 to represent this encounter. Next, two gated recurrent unit layers with attention are used to 209 generate the encounter-level and variable-level attention weights by the softmax function and 210 hyperbolic tangent function, respectively. Finally, RETAIN represents each patient as a context 211 vector that is a summation of all encounters, weighted by encounter-level and variable-level 212 attention. Additionally, to mimic clinical practice, RETAIN takes the input of the EHR data in a 213 reverse chronological order so that the model pays more attention to more recent encounters. A 214 fully connected layer with the softmax activation function is used to calculate the final probability of the class labels, in this study HCC or no HCC. Figure S2 shows the overview of 215 216 RETAIN model. The input of RETAIN model contains the following features in all the included 217 encounters: demographic (age, gender, race, and marital status), diagnosis codes (ICD 9 and ICD 218 10 code), medications in the format of the generic medication name, lab test and clinical event 219 (LOINC code).

Besides RETAIN, we also used a deep learning survival model, DeepHit [25, 26], to predict survival times while taking into account the competing risk of death. DeepHit uses the baseline information of the index date and employed a deep neural network to learn the relationship between the input variables and the distribution of the survival times. Furthermore, DeepHit can handle the competing risk by incorporating cause-specific sub-networks for each event and a shared sub-network to learn the feature representations. The loss function in DeepHit includes 226 the log-likelihood of the joint distribution of the first hitting time and corresponding event. Contrary to our application of RETAIN, we did not pre-process input data for censoring here 227 228 because DeepHit handles censorship explicitly. However, while RETAIN uses the full 229 longitudinal information of each patient for disease prediction, DeepHit only uses baseline 230 information at the time of diagnosis of NAFLD. The complete list of baseline features is shown 231 in **Table S1** in Supplementary Materials. Since DeepHit predicted the risk of HCC at each time 232 point after the index date, to compare DeepHit to RETAIN, we transformed DeepHit outputs into the risk probability for HCC at 10 years after the index date. The Area Under the Receiver 233 234 Operating Characteristic Curve (AUC) was the evaluation metric to benchmark these two 235 methods [24, 36]. DeepHit and RETAIN are representative of two main categories of deep 236 learning-based methods for disease prediction on EHR data: classification-based models that can 237 use time-varying covariates to achieve more accurate predictions but do not properly account for censorship, which would lead to biased estimates of disease risk; deep survival models handle 238 239 censorship properly but lack the capability to utilize time-varying covariates. In this analysis, we 240 are not directly comparing DeepHit and RETAIN, but rather exploring whether modeling timevarying covariates with an unknown time-dependent function can lead to more accurate 241 242 predictions.

243

244 Backward masking

Due to the slow progression of HCC, some telltale signs and symptoms may be recorded in the medical record before a formal diagnosis code is recorded. However, we are interested in identifying risk factors, not well-known signs and symptoms of HCC. To mitigate the impact of delayed diagnosis, we trained multiple models by masking various lengths of medical history backward from the date of HCC diagnosis (Figure 3). This masking led to four subgroups, in
which patient encounters within 0.5, 1, 2, or 4 years before HCC diagnosis or censoring are
masked. We varied the masking length to evaluate how the duration of longitudinal information
after the index date affects disease prediction. By masking different lengths of medical history of
each patient in the NAFLD-to-HCC dataset, we obtained the training and testing data for each



Figure 3. An example of masking various lengths of medical history backward from the date of HCC diagnosis or censoring. For HCC patients (Patient #1 and #3 in Figure 2), the end point is the date of HCC diagnosis. For censored patient without HCC (Patient #2 in Figure 2), the end point is the date of censoring, i.e. the last patient encounter in EHR. Patient #4 in Figure 2 was excluded.

254 masking group to finetune and evaluate the model using five-fold cross validation.

- 256 Transfer learning
- As shown in Table 1, there are only 272 HCC patients in the NAFLD cohort. Since a typical
- 258 deep learning model like RETAIN contains many learnable parameters, this sample would be

259 inadequate for finding an acceptable solution in such a large parameter space. A common approach for circumventing small sample sizes in EHR data is to use a general-purpose 260 261 pretrained model, and fine-tune the embedding layers of the network on the target dataset [13, 262 36]. In this study, we pretrained the whole model on a related prediction task for which a large 263 dataset is available for training [27, 37, 38]. Specifically, we trained the deep learning on the 264 larger case-control set, so that the model learns to recognize general patterns such as early 265 symptoms and complications of HCC development. We then used this pretrained model and fine-266 tuned it on the NAFLD cohort, and we used cross-validation to evaluate the model's 267 performance in predicting HCC among NAFLD patients. We used the same dictionary of 268 medical codes and model architecture during pretraining and finetuning. 269 270 **Aggregated attention scores** The attention scores outputted by the RETAIN model were employed to identify which factors 271 272 contribute more to the prediction of HCC. Specifically, since RETAIN model output the 273 attention scores for each code in all encounters and patients, we first calculated the mean of the 274 attention score of each medical code across encounters for each patient to obtain the code-level 275 importance score for this specific patient. Then we averaged the mean values of each code across

276 different patients to obtain the importance value of each medical code within the cohort. Finally,

277 we ranked the risk factors and protective factors by their cohort-level importance value and

excluded medical codes observed in fewer than 10 patients. We applied this procedure to both

279 male and female patients and identified sex-specific features for HCC progression.

280

281 Results

282 Formulating disease prediction as a classification problem

We compared the performance of two state-of-the-art deep learning algorithms for disease 283 284 prediction: DeepHit and RETAIN. DeepHit incorporates a statistically rigorous competing risk 285 model for fitting time-to-event data, while RETAIN is designed only for classification without 286 consideration for censoring. However, DeepHit only considers covariate values at baseline, 287 whereas RETAIN tracks changes in covariates across time. Since we are particularly interested in identifying risk factors and protective factors, rather than estimating absolute disease risk, we 288 formulated disease prediction as a classification problem at a specified time point while 289 290 accounting for censoring (Methods, Figure 2). We showed with Monte Carlo simulations that 291 analyzing time-to-event data as a classification problem in this way allows us to identify risk 292 factors reliably with strong control of type I error (Supplementary Figure S3-5). 293 Modeling time-varying covariate improves disease prediction 294 We evaluated the predictive performance of RETAIN and DeepHit by five-fold cross-validation. 295 296 Overall, RETAIN achieved a consistently high AUC score of ~0.95 on all patients, male patients, 297 and female patients, outperforming DeepHit (Figure 4). The error bars show the standard 298 deviations of the AUC scores across 5 folds. When considering all patients or men only, 299 RETAIN outperformed DeepHit by about 0.1 in AUC score. Among female patients, RETAIN outperformed DeepHit by ~0.21 in AUC score. We hypothesized that RETAIN outperformed 300 301 DeepHit because the RETAIN model used more longitudinal information. Henceforth, we focused on evaluating the performance characteristics of the much superior deep learning model, 302

303 RETAIN.



Figure 4. Predict HCC occurrence in NAFLD patients using RETAIN and DeepHit. All patients, male patients alone, or female patients alone were used respectively from the NAFLD cohort. Bars is the mean and error bars is the standard deviation of AUC from 5-fold cross-validation. The RETAIN model used covariate values from encounters up to 0.5 year before HCC diagnosis or censoring; DeepHit used only covariate values at baseline.

305

To test our hypothesis that time-varying covariates are critical to the superior predictive performance of RETAIN, we performed backward masking on the covariate data. That is, we masked data derived from encounters that occurred within 0.5, 1.0, 2.0, or 4.0 years before the date of disease diagnosis (or the final encounter for patients who never developed HCC). Hence,

310	as we increased the masking length, more longitudinal information is withheld from the RETAIN
311	model. With longer backward masking, the average length of an available patient's medical
312	history decreased. Concomitant with less longitudinal information (i.e. shorter medical history
313	and fewer available encounters), the AUC score of RETAIN decreased from 0.966 to 0.906 for
314	models evaluated with cross-validation on all patients (Table 2). Even larger performance
315	reductions were observed for models trained and evaluated on only male or only female patients.
316	The AUC decreased to 0.838 and 0.828 for men and women, respectively. With 4 years of
317	backward masking, < 3 years of longitudinal data were available to RETAIN, which caused the
318	AUC performance of RETAIN to decline to comparable levels as those achieved by DeepHit
319	using only baseline covariates (Table 2, Figure 4). Taken together, these results indicate that
320	RETAIN relies on the use of time-varying covariate values beyond baseline to achieve superior
321	performance.

322

323 Table 2. The performance characteristics of RETAIN for different lengths of backward masking.

Masking length (yrs)		0.5	1.0	2.0	4.0
Madiaal history (una)	Mean	7.16	6.37	5.14	2.93
Meaicai history (yrs)	Median	7.27	6.43	5.05	2.84
	All	0.966(0.019)	0.955(0.008)	0.945(0.023)	0.906(0.026)
Mean AUC (SD)	Male	0.942(0.036)	0.908(0.035)	0.914(0.046)	0.838(0.057)
	Female	0.952(0.027)	0.920(0.036)	0.927(0.023)	0.828(0.101)

324

325 Transfer learning improves model performance.

326	We evaluated the extent to which transfer learning improved RETAIN performance. In our
327	NAFLD cohort, only 2 of 1000 NAFLD patients developed HCC after 10 years beyond the index
328	date. Due to the rare incidence of HCC among NAFLD patients, we pretrained RETAIN models
329	on the larger set of patients who developed HCC (excluding NAFLD patients) and control

330 patients who never developed HCC. We then fine-tuned these pretrained models on the NAFLD cohort. With transfer learning, AUC performances substantially increased, with improvements in 331 332 AUC ranging from 0.019 to 0.095 across different lengths of backward masking (Table 3). The 333 paired T-test was conducted to measure the statistical significance of using TL under different 334 conditions in the AUC scores from 5 folds. The AUC after TL was subtracted from the AUC 335 before TL, so the alternative hypothesis assumes that the mean difference of AUC after using TL is less than zero, which means the AUC after TL is larger than the AUC without TL. The 336 improvement was statistically significant with Transfer Learning under many conditions. 337 338 Transfer learning also reduced the validation loss (Supplementary Figure S6). These results 339 indicate that RETAIN learned generalizable patterns from the larger case-control HCC dataset 340 and that this information helped RETAIN achieved better performance on the smaller cohort of 341 interest. Furthermore, greater improvements were observed with longer backward masking 342 (Table 3). For example, the AUC improved 0.065 and 0.08 with less than 2 years masking for male and female patients, respectively. However, the improvements were just 0.019 and 0.038 343 344 with 0.5 year of backward masking. Moreover, models applied only in women achieved consistently higher improvement than models applied only in men, irrespective of masking 345 346 length (Table 3).

Masking	Al	1	М	ale	Fer	nale
length (yrs)	without TL	with TL	without TL	with TL	without TL	with TL
0.5	0.932(0.020)	0.966(0.019)***	0.923(0.027)	0.942(0.036)	0.914(0.045)	$0.952(0.027)^{*}$
1.0	0.900(0.042)	$0.955(0.008)^{*}$	0.867(0.046)	$0.908(0.035)^{*}$	0.873(0.031)	$0.920(0.036)^{*}$
2.0	0.918(0.028)	$0.945(0.023)^{*}$	0.849(0.047)	0.914(0.046)	0.847(0.063)	$0.927(0.023)^{*}$
4.0	0.877(0.024)	$0.906(0.026)^{*}$	0.801(0.028)	0.838(0.057)	0.733(0.139)	0.828(0.101)

348 Table 3. AUC performances of RETAIN models with and without transfer learning (TL).

Cell values contain mean (SD) of cross-validation AUC. * The p-value of paired T-test with TL is less than 0.05, ***
 The p-value is less than 0.001. The alternative hypothesis assumes that the mean difference of AUC after using TL is less than zero.

352

353 Sex bias impacts model performance

354 Gender disparity in HCC morbidity and survival outcome has been extensively studied and 355 documented [10, 39-43]. However, Prior studies on HCC risk were either small [3, 4] or sexbiased where 94.4% of patients in the study were male [31], which may have led to biased 356 357 results. Therefore, investigating sex bias in HCC can improve our understanding of how sex-358 based differences affect outcomes and help ensure data fairness in AI applications [40, 44]. To 359 assess how sex bias in data affects the performance of deep learning, we trained RETAIN models 360 on one sex and evaluated them in the other sex. As shown in **Table 4**, the model trained using male patients achieved inferior performance in female patients, as the AUC decreased from 361 362 0.927 to 0.834 with 2 years of backward masking. When applying the model trained on female 363 patients with 4 years of backward masking, the performance for male prediction decreased from 0.838 to 0.773. These results are consistent with the concept that sex influences HCC risk, and 364 365 there could be male- and female-specific features learned by the model that can only perform 366 well in predicting HCC risks in that sex. As expected, the model trained on the data with both sexes achieved better performance than that trained on the data for either sex alone. 367

Predicted group	Tugingd with	Masking length (years)					
Predicied group	I ramed with	0.5	1	2	4		
	All*	0.965(0.030)	0.948(0.019)	0.931(0.041)	0.900(0.050)		
Male	Male	0.942(0.036)	0.908(0.035)	0.914(0.046)	0.838(0.057)		
	Female	0.890(0.059)	0.848(0.051)	0.873(0.046)	0.773(0.065)		
	All	0.964(0.018)	0.964(0.014)	0.960(0.026)	0.916(0.009)		
Female	Male	0.905(0.038)	0.878(0.040)	0.834(0.028)	0.806(0.086)		
	Female	0.952(0.027)	0.920(0.036)	0.927(0.023)	0.828(0.101)		

369 Table 4. The performance of RETAIN trained and evaluated on different subgroups. The scores are the 370 average AUC (SD) from cross-validation.

371 * Trained on both male and female patients.

372

373 **Sex-specific features**

374 To understand why RETAIN achieves different predictive performances in male vs. female 375 patients, we analyzed aggregated attention scores obtained from the model. As shown in **Table** 376 **S2-S5** in Supplementary Materials, we identified medical codes with positive attention scores 377 and negative attention scores for male and female patients. Some common and well-known risk 378 factors or complications of HCC are ranked high in all patients, e.g., high body mass index, 379 abnormal aspartate transferase values, and the presence of type 2 diabetes mellitus. Specifically 380 for women, rheumatoid arthritis is associated with positive attention scores, and kidney stones 381 are associated with negative attention scores.

To illustrate how RETAIN makes a specific prediction, in Figure 5 we depict the attention 382

scores of codes for a specific patient who developed HCC, which was correctly predicted. We 383

filtered out the codes whose attention scores are between the 25th percentile and the 75th 384

385 percentile in all encounters to make the figure readable. In the RETAIN prediction for this

patient, normal lab results for tests such as platelet count and aspartate transferase were possible 386

387 protective factors, whereas type 2 diabetes, hypertension, and elevated aspartate transferase were

388 possible risk factors. Being a non-smoker was associated with a positive attention score.



Figure 5. Visualization of RETAIN attention scores for a patient. Codes with attention scores higher than 75th percentile or lower than 25th percentile in at least one encounter are plotted. The color range represents the associated attention scores from the model. "BMI error" means the BMI value in the EHR database is invalid (negative or empty). AHD: Atherosclerotic Heart Disease. OMI: Old Myocardial Infarction.

389

390 Discussion

We highlight key areas of innovation in our work for the application of deep learning in medical 391 informatics. To compare deep learning algorithms using the same evaluation measure, we 392 393 formulated disease prediction as a classification problem while taking censoring into account. To 394 account for delayed disease diagnosis, we propose a backward masking approach, which 395 prevents deep learning models that incorporate time-varying covariates from identifying telltale 396 signs and symptoms of the disease rather than risk factors. Additionally, we showed that incorporating time-varying covariates with a deep learning model, such as RETAIN, can 397 398 improve the AUC performance of the classification-based disease prediction. We then

399 demonstrate that transfer learning improves predictive performance when the data set is limited by having insufficient number of cases. Further, we demonstrated that sex bias adversely impacts 400 401 deep learning performance, and we identified sex-specific features for HCC progression. 402 Delayed diagnosis is common in clinical practice, and failure to take this issue into account 403 may cause deep learning algorithms to identify trivial features that are not of interest to the 404 clinical community. Patients have prescribed medications or diagnosed with symptoms for some 405 diseases, but the actual entry of the diagnosis code for this disease can be delayed for quite some 406 time due to factors including laboratory test confirmation and clerical errors. This delayed entry 407 of the diagnosis code thus allows deep learning algorithms to predict disease status effortlessly 408 using telltale symptoms or prescribed medications for the disease. To mitigate this issue, we 409 designed a new masking strategy to investigate how delayed diagnosis impacts deep learning 410 models that use longitudinal information. When we mask for a sufficient length of time before 411 the formal diagnosis of the disease, we can prevent deep learning algorithms from using trivial 412 features of the disease and allow the algorithms to identify more subtle patterns of features that 413 help us gain critical clinical insights into the etiology and progression of the disease. Although 414 some survival analyses can use the time-varying variates to make predictions at different time 415 points (horizons) prior to death by manual feature selection, this is different from our design 416 which aims to solve the issue of delayed diagnosis and telltale symptoms [45]. 417 Using backward masking, we demonstrated that modeling time-varying covariate of features 418 contributes strongly to disease prediction. When we masked patient encounters that occurred 419 within four years of HCC diagnosis, the predictive performance of RETAIN (which models

420 time-varying features) decreased to similar levels as that of DeepHit (which only models

421 baseline features). This finding indicates that the improved disease prediction performance of

422 RETAIN over DeepHit is due to the modeling of time-varying covariate of the features.

423 Accordingly, incorporating time-varying covariates can be key to achieving optimal performance
424 for disease prediction.

425 Furthermore, we showed that transfer learning can be used to remedy the rarity of positive 426 examples. We recognized that despite beginning with a large cohort of millions of patients, the 427 subset of patients who experienced the outcome event is relatively small. Different from the prior studies which typically adopt the embedding vectors of medical codes learned from a general 428 429 task [27] or finetune a large pretrained model which was trained on diverse but unrelated medical 430 conditions [28], we first trained a randomly initialized model on a related problem with large 431 sample size, and finetuned the trained model on the target problem. We demonstrated that the 432 application of this transfer learning strategy yielded a remarkable improvement in predictive performance. This improvement also indicates that although the larger, related dataset contains 433 cases that are not of primary interest, they may share general patterns that help deep learning 434 algorithms discern the disease of interest. Pretraining on the larger, related dataset thus improved 435 436 prediction on the smaller target dataset.

437

438 Acknowledgements

439 This work is partly supported by the National Institutes of Health (NIH) through grant

440 1UL1TR003167, 1R01AG066749-01, DoD W81XWH2210164 and the Cancer Prevention and

441 Research Institute of Texas through grant RP170668 (WJZ). W.J.Z. conceived of the project.

442 W.J.Z., D.J.H.S. and Z.L. designed and coordinated the study. Z.L., L. Lan, and Y.Z.

⁴⁴³ preprocessed the data. Z.L. performed the deep learning model training and evaluation. R.L.

444 performed the statistical simulations. K.D.C provided clinical advice. L. Li provided statistical

445	guidance for the study. D.J.H.S., Z.L., L. Lan, and R.L. wrote the manuscript. All authors read
446	and approved the final manuscript. We acknowledge the use of "Cerner Health Facts®" and the
447	assistance provided by UTHealth SBMI Data Service team to extract data.
448	

449 Conflicts of Interest

450 None declared.

References

- 1. Forner A, Llovet JM, Bruix J: Hepatocellular carcinoma. *The Lancet (British edition)* 2012, **379**(9822):1245-1255.
- Venook AP, Papandreou C, Furuse J, Ladrón de Guevara L: The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective. The oncologist (Dayton, Ohio) 2010, 15(S4):5-13.
- 3. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA: Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. *Gastroenterology* 2011, **140**(1):124-131.
- Ertle J, Dechêne A, Sowa JP, Penndorf V, Herzer K, Kaiser G, Schlaak JF, Gerken G, Syn WK, Canbay A: Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. International journal of cancer 2011, 128(10):2436-2443.
- Choi E, Bahadori MT, Schuetz A, Stewart WF, Sun J: Doctor AI: Predicting Clinical Events via Recurrent Neural Networks. JMLR workshop and conference proceedings 2016, 56:301-318.
- Ioannou GN, Tang W, Beste LA, Tincopa MA, Su GL, Van T, Tapper EB, Singal AG, Zhu J, Waljee AK: Assessment of a deep learning model to predict hepatocellular carcinoma in patients with hepatitis C cirrhosis. JAMA network open 2020, 3(9):e2015626e2015626.
- Phan DV, Chan CL, Li AHA, Chien TY, Nguyen VC: Liver cancer prediction in a viral hepatitis cohort: A deep learning approach. International Journal of Cancer 2020, 147(10):2871-2878.
- Nam JY, Sinn DH, Bae J, Jang ES, Kim J-W, Jeong S-H: Deep learning model for prediction of hepatocellular carcinoma in patients with HBV-related cirrhosis on antiviral therapy. JHEP Reports 2020, 2(6):100175.
- Ahn JC, Qureshi TA, Singal AG, Li D, Yang J-D: Deep learning in hepatocellular carcinoma: Current status and future perspectives. World Journal of Hepatology 2021, 13(12):2039.
- 10. Huang FY, Wong DK, Seto WK, Lai CL, Yuen MF: Estradiol induces apoptosis via activation of miRNA-23a and p53: implication for gender difference in liver cancer development. *Oncotarget* 2015, 6(33):34941-34952.
- 11. Shah PA, Patil R, Harrison SA: **NAFLD-related hepatocellular carcinoma: The growing challenge**. *Hepatology* 2022.
- 12. Shickel B, Tighe PJ, Bihorac A, Rashidi P: **Deep EHR: a survey of recent advances in deep learning techniques for electronic health record (EHR) analysis**. *IEEE journal of biomedical and health informatics* 2017, **22**(5):1589-1604.
- 13. Si Y, Du J, Li Z, Jiang X, Miller T, Wang F, Zheng WJ, Roberts K: **Deep representation learning of patient data from Electronic Health Records (EHR): a systematic review**. *arXiv preprint arXiv:201002809* 2020.

- 14. Tran T, Nguyen TD, Phung D, Venkatesh S: Learning vector representation of medical objects via EMR-driven nonnegative restricted Boltzmann machines (eNRBM). *Journal of biomedical informatics* 2015, **54**:96-105.
- Choi E, Bahadori MT, Schuetz A, Stewart WF, Sun J: Doctor ai: Predicting clinical events via recurrent neural networks. In: *Machine Learning for Healthcare Conference: 2016*. 301-318.
- 16. Choi E, Xu Z, Li Y, Dusenberry MW, Flores G, Xue Y, Dai AM: **Graph Convolutional Transformer: Learning the Graphical Structure of Electronic Health Records**. *arXiv preprint arXiv:190604716* 2019.
- 17. Klein JP, Moeschberger ML, collection EBe: **Survival Analysis : Techniques for Censored and Truncated Data**, 2nd 2003. edn. New York, NY: Springer New York : Imprint: Springer; 2003.
- Schluchter MD, Greene T, Beck GJ: Analysis of change in the presence of informative censoring: application to a longitudinal clinical trial of progressive renal disease. Statistics in medicine 2001, 20(7):989-1007.
- 19. Vock DM, Wolfson J, Bandyopadhyay S, Adomavicius G, Johnson PE, Vazquez-Benitez G, O'Connor PJ: Adapting machine learning techniques to censored time-to-event health record data: A general-purpose approach using inverse probability of censoring weighting. *Journal of biomedical informatics* 2016, **61**:119-131.
- 20. Katzman JL, Shaham U, Cloninger A, Bates J, Jiang T, Kluger Y: **DeepSurv: personalized** treatment recommender system using a Cox proportional hazards deep neural network. *BMC medical research methodology* 2018, **18**(1):1-12.
- 21. Craig E, Zhong C, Tibshirani R: **Survival stacking: casting survival analysis as a classification problem**. *arXiv preprint arXiv:210713480* 2021.
- 22. Zhong C, Tibshirani R: **Survival analysis as a classification problem**. *arXiv preprint arXiv:190911171* 2019.
- 23. Ofosu A, Ramai D, Reddy M: Non-alcoholic fatty liver disease: controlling an emerging epidemic, challenges, and future directions. *Ann Gastroenterol* 2018, **31**(3):288-295.
- 24. Choi E, Bahadori MT, Sun J, Kulas J, Schuetz A, Stewart W: **Retain: An interpretable predictive model for healthcare using reverse time attention mechanism**. In: *Advances in Neural Information Processing Systems: 2016*. 3504-3512.
- 25. Lee C, Yoon J, Van Der Schaar M: Dynamic-deephit: A deep learning approach for dynamic survival analysis with competing risks based on longitudinal data. *IEEE Transactions on Biomedical Engineering* 2019, 67(1):122-133.
- 26. Lee C, Zame W, Yoon J, van der Schaar M: **Deephit: A deep learning approach to survival analysis with competing risks**. In: *Proceedings of the AAAI Conference on Artificial Intelligence: 2018*.
- 27. Xiang Y, Xu J, Si Y, Li Z, Rasmy L, Zhou Y, Tiryaki F, Li F, Zhang Y, Wu Y: **Time-sensitive clinical concept embeddings learned from large electronic health records**. *BMC medical informatics and decision making* 2019, **19**(2):139-148.
- 28. Rasmy L, Xiang Y, Xie Z, Tao C, Zhi D: Med-BERT: pretrained contextualized embeddings on large-scale structured electronic health records for disease prediction. *NPJ digital medicine* 2021, **4**(1):1-13.

- 29. Xue Y, Du N, Mottram A, Seneviratne M, Dai AM: Learning to select best forecast tasks for clinical outcome prediction. *Advances in Neural Information Processing Systems* 2020, **33**:15031-15041.
- 30. Murphy KP: Machine learning: a probabilistic perspective: MIT press; 2012.
- 31. Kanwal F, Kramer JR, Mapakshi S, Natarajan Y, Chayanupatkul M, Richardson PA, Li L, Desiderio R, Thrift AP, Asch SM *et al*: **Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease**. *Gastroenterology* 2018, **155**(6):1828-1837.e1822.
- 32. Pittet D, Wyssa B, Herter-Clavel C, Kursteiner K, Vaucher J, Lew PD: Outcome of diabetic foot infections treated conservatively: a retrospective cohort study with long-term follow-up. Arch Intern Med 1999, **159**(8):851-856.
- 33. White IK, Shaikh KA, Moore RJ, Bullis CL, Sami MT, Gianaris TJ, Fulkerson DH: **Risk of** radiation-induced malignancies from **CT** scanning in children who underwent shunt treatment before 6 years of age: a retrospective cohort study with a minimum 10-year follow-up. J Neurosurg Pediatr 2014, **13**(5):514-519.
- Yu Z, Chen J, Cheng X, Xie D, Chen Y, Zou X, Peng X: Patients with degenerative cervical myelopathy exhibit neurophysiological improvement upon extension and flexion: a retrospective cohort study with a minimum 1-year follow-up. *BMC Neurol* 2022, 22(1):110.
- 35. Ranganath R, Perotte A, Elhadad N, Blei D: **Deep survival analysis**. In: *Machine Learning for Healthcare Conference: 2016*. PMLR: 101-114.
- 36. Rasmy L, Wu Y, Wang N, Geng X, Zheng WJ, Wang F, Wu H, Xu H, Zhi D: A study of generalizability of recurrent neural network-based predictive models for heart failure onset risk using a large and heterogeneous EHR data set. *Journal of biomedical informatics* 2018, **84**:11-16.
- 37. Gopalakrishnan K, Khaitan SK, Choudhary A, Agrawal A: **Deep Convolutional Neural Networks with transfer learning for computer vision-based data-driven pavement distress detection**. *Construction and Building Materials* 2017, **157**:322-330.
- 38. Pan SJ, Yang Q: **A survey on transfer learning**. *IEEE Transactions on knowledge and data engineering* 2009, **22**(10):1345-1359.
- 39. Wu EM, Wong LL, Hernandez BY, Ji JF, Jia W, Kwee SA, Kalathil S: **Gender differences in** hepatocellular cancer: disparities in nonalcoholic fatty liver disease/steatohepatitis and liver transplantation. *Hepatoma research* 2018, **4**.
- 40. Li Y, Xu A, Jia S, Huang J: Recent advances in the molecular mechanism of sex disparity in hepatocellular carcinoma. *Oncology letters* 2019, **17**(5):4222-4228.
- 41. Mauvais-Jarvis F, Bairey Merz N, Barnes PJ, Brinton RD, Carrero JJ, DeMeo DL, De Vries GJ, Epperson CN, Govindan R, Klein SL *et al*: **Sex and gender: modifiers of health, disease, and medicine**. *Lancet* 2020, **396**(10250):565-582.
- 42. Costa AR, Lança de Oliveira M, Cruz I, Gonçalves I, Cascalheira JF, Santos CRA: **The Sex Bias of Cancer**. *Trends in endocrinology and metabolism: TEM* 2020, **31**(10):785-799.
- 43. Pan JJ, Fallon MB: **Gender and racial differences in nonalcoholic fatty liver disease**. *World journal of hepatology* 2014, **6**(5):274-283.
- 44. Bellamy RK, Dey K, Hind M, Hoffman SC, Houde S, Kannan K, Lohia P, Martino J, Mehta S, Mojsilovic A: **AI Fairness 360: An extensible toolkit for detecting, understanding, and mitigating unwanted algorithmic bias**. *arXiv preprint arXiv:181001943* 2018.

45. Schwab P, Mehrjou A, Parbhoo S, Celi LA, Hetzel J, Hofer M, Schölkopf B, Bauer S: **Realtime prediction of COVID-19 related mortality using electronic health records**. *Nat Commun* 2021, **12**(1):1058.

Abbreviations

- **EHR**: electronic health records
- NAFLD: nonalcoholic fatty liver disease
- HCC: hepatocellular carcinoma
- AUC: Area Under the Receiver Operating Characteristic Curve